NCT00254332

Completed

Effect of Denileukin Diftitox on Immune System in CTCL Patie...

University of Pittsburgh Source

Other study identifiers

Sponsor study identifier

IRB 0509084

Study Type

observational

Estimated enrollment

10

Locations

1 country

Sites

1

Timeline

Study Start

November 2005

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

Not reported

Date not reported

Study Completion

September 2007

Date type not reported

This date has not been verified as actual or estimated.

Brief Summary

This is a blood and tissue study to determine the effect of the drug called denileukin diftitox on the immune system cells that may be involved in patient response to their cutaneous t-cell lymphoma. Patients who are undergoing standard of care therapy with denileukin diftitox will be invited to participate. Blood and tissue samples will be obtained at baseline, day 5 and day 19 in up to the first 4 cycles of denileukin diftitox.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Estimated enrollment: 10 participants
Study completion date: September 2007
Date type not reported
This date has not been verified as actual or estimated.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
November 2005
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
November 15, 2005
Actual (reported)
First Posted
November 16, 2005
Actual (reported)
Study Completion
September 2007
Date type not reported
This date has not been verified as actual or estimated.

Last Updated: March 25, 2015
Status Verified: December 2007
Last Update Submitted: March 24, 2015

Conditions

Cutaneous T-cell Lymphoma Mycosis Fungoides Sezary Syndrome

Keywords

Cutaneous T-cell LymphomaSezary SyndromeMycosis FungoidesDenileukin Diftitox

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

and older
diagnosed with CTCL

Sponsors & Collaborators

University of Pittsburgh
Otherlead

Study Sites (1)

University of Pittsubrgh Medical Center

Pittsburgh, Pennsylvania, 15213, United States

MeSH Terms

Conditions

Lymphoma, T-Cell, CutaneousSezary SyndromeMycosis Fungoides

Condition Hierarchy (Ancestors)

Lymphoma, T-CellLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

Larisa J. Geskin, M.D.
University of Pittsburgh
PRINCIPAL INVESTIGATOR

Study Design

Study Type: observational
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER

Study Record Dates

First Submitted

November 15, 2005

First Posted

November 16, 2005

Study Start

November 2005

Date type not reported

This date has not been verified as actual or estimated.

Study Completion

September 2007

Date type not reported

NCT00091559

Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

Phase 2Completed

NCT02341209

Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma

Phase 2Terminated

NCT00099593

Immunization Against Tumor Cells in Sezary Syndrome

Phase 2Completed

NCT00177268

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

Recruiting

NCT07213882

A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)

Early Phase 1Not Yet Recruiting

NCT04955340

A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat

Phase 1Completed

able and willing to provide informed consent

will be receiving denileukin diftitox per standard guidelines

You may not qualify if:

prior history of receiving Ontak
pregnancy

Contact the study team to confirm eligibility.

This date has not been verified as actual or estimated.

Last Updated

March 25, 2015

Record last verified: 2007-12

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00254332
Data provider: ClinicalTrials.gov
Source updated: 2015-03-25
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:26:02 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Study Completion

Conditions

Keywords

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations